Screening and Identification of Biomarkers in Ascites Related to Intrinsic Chemoresistance of Serous Epithelial Ovarian Cancers

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Huang, He ^a   Li, Yujie ^a   Liu, Jihong ^a   Zheng, Minghui ^b   Feng, Yanling ^a   Hu, Kunhua ^c   Huang, Yongwen ^a   Huang, Qidan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A4; CARBOPLATIN; CERULOPLASMIN; CISPLATIN; DOXEPACLITAXEL; HAPTOGLOBIN; PACLITAXEL; PREALBUMIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASCITES TUMOR; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; GEL ELECTROPHORESIS; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEROUS EPITHELIAL OVARIAN CANCER; TWO DIMENSIONAL FLUORESCENCE IN GEL ELECTROPHORESIS; UPREGULATION;

ADULT; AGED; ASCITES; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84870925061     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051256     Document Type: Article

References (24)

1. Hall MD, Amjadi S, Zhang M, Beale PJ, Hambley TW, (2004) The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines. J Inorg Biochem 98: 1614-1624.
2. Berek JS, Hacker NF (2010) Berek & Hacker's gynecologic oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health. 895 p.
3. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, et al. (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971.
4. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, et al. (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11: 6300-6310.
5. Jacobs IJ, Menon U, (2004) Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3: 355-366.
6. Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, et al. (2007) Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res 6: 4549-4555.
7. Liu W, Zhou XW, Liu S, Hu K, Wang C, et al. (2009) Calpain-truncated CRMP-3 and-4 contribute to potassium deprivation-induced apoptosis of cerebellar granule neurons. Proteomics 9: 3712-3728.
8. Spriggs D, (2003) Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 90: S39-S44.
9. Adam RA, Adam YG, (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198: 999-1011.
10. Kassis J, Klominek J, Kohn EC, (2005) Tumor microenvironment: what can effusions teach us? Diagn Cytopathol 33: 316-319.
11. Liotta LA, Kohn EC, (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379.
12. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, et al. (2002) Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161: 1917-1924.
13. Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, et al. (2008) A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 7: 339-351.
14. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, et al. (2009) Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics 8: 661-669.
15. Petricoin EE, Paweletz CP, Liotta LA, (2002) Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 7: 433-440.
16. Altinoz MA, Korkmaz R, (2004) NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 51: 239-247.
17. Woong-Shick A, Sung-Pil P, Su-Mi B, Joon-Mo L, Sung-Eun N, et al. (2005) Identification of hemoglobin-alpha and-beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci 96: 197-201.
18. Bachvarov D, LEsperance S, Popa I, Bachvarova M, Plante M, et al. (2006) Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol 29: 919-933.
19. Nayak SB, Bhat VR, Upadhyay D, Udupa SL, (2003) Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol 47: 108-110.
20. Kluger HM, Kluger Y, Gilmore-Hebert M, DiVito K, Chang JT, et al. (2004) cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest 84: 320-331.
21. Chakravarty PK, Ghosh A, Chowdhury JR, (1986) Evaluation of ceruloplasmin concentration in prognosis of human cancer. Acta Med Okayama 40: 103-105.
22. Onizuka K, Migita S, Yamada H, Matsumoto I, (1999) [Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor]. Fukuoka Igaku Zasshi 90: 46-58.
23. Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, et al. (2001) The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 111: 696-701.
24. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, et al. (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9: 1666-1672.